Aescap Life Sciences Fund
Investing in high-growth biotech companies
The Aescap Life Sciences Fund was launched on March 28, 2016. This open-end fund invests in biotech companies that develop and market next generation medical treatments.
The biotech market is a large and fast-growing market. This is driven by:
- Ageing population.
- Increased demand for ‘Western’ medicine in the emerging markets.
- Growing pressure on healthcare (costs and staff) which can be reduced by new and better medicines.
The Life Sciences Fund is managed by an experienced investment team with several team members having over 30 years experience and an excellent track record. The fund has an average annual net performance target of 20% over the mid-term (4-5 years).
An investment in the fund will not only allow for a good return on investment. It also enables the development of better treatments for diseases with a high unmet medical need such as ALS, Alzheimer’s, Arthritis, Cancer, MS, Parkinson’s and many others.